Guardian Pharmacy Services, Inc.

NYSE:GRDN

Medical - Distribution

Healthcare
$48.84 +0.39%

+$0.17 today

Market cap
$3.09B
Beta
0.08
P/E (TTM)
52.0
EPS (TTM)
$0.84
52W Low $19.30High $44.00

Volume 0.45M

Average 0.48M

GRDN Pre-Tax Margin

Income before tax as a percentage of revenue.

Guardian Pharmacy Services, Inc.NYSE: GRDN

Pre-Tax Margin · Q2 FY2026 · quarter ended Jun 2026

Pre-tax margin widens to 8.5%

Pre-tax margin was 8.5% in Q2 FY2026, up 4.8 pp from a year earlier. On a trailing-twelve-month basis it was 6.5%, up 11.4 pp year over year. Over 3 fiscal years it narrowed by 0.4 pp.

Context

  • Pre-tax margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
8.5%+3.0 pp QoQ
Last fiscal yearDec 2025
5.1%+10.5 pp YoY
LTMJun 2026
6.5%+11.4 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+4.8 pp——
1 year+10.5 pp——
3 years-0.4 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
5.1%
Year-over-year change
+10.5pp

Pre-Tax Margin vs competitors

How GRDN compares with its peers on the latest reported figures

  • GRDN's LTM Jun 2026 pre-tax margin of 6.5% is the 3rd highest of the 10 companies compared; the peer median is -31.8%.
  • Its year-over-year change of +11.4 pp is the 4th highest of 10, against a peer median of +0.9 pp.
  • Over three fiscal years its change of -0.4 pp compares with a peer median of +16.7 pp.
GRDN Competitors Peer median
Pre-Tax Margin for GRDN and competitors
Company Period LTM level YoY 3-year change
MDPediatrix Medical Group, Inc.LTM Sep 202610.4% -0.2 pp+7.2 pp
NHCNational HealthCare CorporationLTM Sep 20269.5% +0.4 pp+8.2 pp
GRDNGuardian Pharmacy Services, Inc.LTM Jun 20266.5% +11.4 pp-0.4 pp
TXG10x Genomics, Inc.LTM Sep 2026-10.5% +0.9 pp+25.2 pp
TWSTTwist Bioscience CorporationLTM Sep 2026-28.4% -8.0 pp+54.6 pp
PRCTPROCEPT BioRobotics CorporationLTM Mar 2026-31.8% +4.4 pp+85.2 pp
QDELQuidelOrtho CorporationLTM Mar 2026-44.3% -32.0 pp-63.1 pp
MESOMesoblast LimitedLTM Jun 2026-47.5% +544.5 pp+1047.2 pp
NUVBNuvation Bio Inc.LTM Jun 2026-88.2% +1325.2 pp—
JANXJanux Therapeutics, Inc.LTM Mar 2026-529.7% +303.0 pp-404.0 pp
EWTXEdgewise Therapeutics, Inc.FY2025— ——
Peer median (excluding GRDN) -31.8%+0.9 pp+16.7 pp

Competitors are the stored peer set for GRDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue792.07M908.91M1.05B1.23B1.45B
Cost of Revenue630.81M723.04M837.88M984.04M1.17B
Gross Profit161.27M185.87M208.31M244.37M282.04M
Gross Margin20.4%20.4%19.9%19.9%19.5%
Research & Development00000
Selling, General & Admin131.12M133.88M167.36M307.29M193.13M
Operating Expenses131.12M133.88M167.36M307.29M193.13M
Depreciation & Amortization16.53M16.56M18.23M19.77M22.34M
EBITDA46.49M68.15M58.81M(43.43M)96.42M
EBITDA Margin5.9%7.5%5.6%-3.5%6.7%
Operating Income30.15M51.99M40.95M(62.92M)88.91M
Operating Margin3.8%5.7%3.9%-5.1%6.1%
Interest Income00000
Interest Expense1.64M1.93M2.86M3.28M665K
Other Income / Expenses(1.82M)(2.33M)(3.23M)(3.56M)(15.49M)
Income Before Tax28.33M49.66M37.72M(66.48M)73.42M
Pre-Tax Margin3.6%5.5%3.6%-5.4%5.1%
Income Tax Expense0004.56M24.47M
Net Income16.31M35.42M23.9M(87.29M)49.22M
Net Margin2.1%3.9%2.3%-7.1%3.4%
EPS (Basic)0.270.580.39(1.77)0.79
EPS (Diluted)0.270.580.39(1.77)0.78
Weighted Avg Shares60.84M60.84M60.84M62.01M62.39M
Weighted Avg Shares (Diluted)60.84M60.84M60.84M62.01M63.3M

Guardian Pharmacy Services, Inc.

NYSE:GRDN

Intrinsic Alpha fair value

Locked

Current Price

$48.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.